Cargando…

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens

Trastuzumab is associated with cardiotoxicity, manifesting as a decrease of the left-ventricular ejection fraction (LVEF). Administration of anthracyclines prior to trastuzumab increases risk of cardiotoxicity. High-sensitive troponin T and N-terminal-pro-brain natriuretic peptide (NT-proBNP) are mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Vries Schultink, Aurelia H. M., Boekhout, Annelies H., Gietema, Jourik A., Burylo, Artur M., Dorlo, Thomas P. C., van Hasselt, J. G. Coen, Schellens, Jan H. M., Huitema, Alwin D. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953989/ https://www.ncbi.nlm.nih.gov/pubmed/29429038 http://dx.doi.org/10.1007/s10928-018-9579-8

Ejemplares similares

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment
por: de Vries Schultink, A. H. M., et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2019)

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
por: van Hasselt, J. G. Coen, et al.
Publicado: (2014)

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”
por: van Hasselt, J. G. Coen, et al.
Publicado: (2015)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
por: Yersal, Özlem, et al.
Publicado: (2018)

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
por: van der Heijden, Lisa, et al.
Publicado: (2022)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy
por: Wasielewski, Marijke, et al.
Publicado: (2014)

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
por: van Eijk, Maarten, et al.
Publicado: (2022)

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
por: Shen, Songjie, et al.
Publicado: (2017)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2019)

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial
por: Joerger, M, et al.
Publicado: (2010)

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab
por: Altomare, Claudia, et al.
Publicado: (2021)

Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer
por: Boekel, Naomi B., et al.
Publicado: (2018)

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin
por: van Hasselt, JGC, et al.
Publicado: (2015)

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin
por: van Hasselt, JGC, et al.
Publicado: (2015)

Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
por: Obasi, Mary, et al.
Publicado: (2021)

Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice
por: Simeoli, Raffaele, et al.
Publicado: (2022)

Semi-mechanistic Modeling of Hypoxanthine, Xanthine, and Uric Acid Metabolism in Asphyxiated Neonates
por: Chu, Wan-Yu, et al.
Publicado: (2022)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
por: Damoiseaux, David, et al.
Publicado: (2023)

Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines
por: Ishii, Taisuke, et al.
Publicado: (2022)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
por: Crombag, Marie-Rose B.S., et al.
Publicado: (2016)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab
por: Dobson, Rebecca, et al.
Publicado: (2021)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
por: Bowles, Erin J. Aiello, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sq3djmuq1qqve4csu1fphusoe9